Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study.

OBJECTIVE Clinical and preclinical evidence suggests a hyperactive glutamatergic system in clinical depression. Recently, the metabotropic glutamate receptor 5 (mGluR5) has been proposed as an attractive target for novel therapeutic approaches to depression. The goal of this study was to compare mGluR5 binding (in a positron emission tomography [PET] study) and mGluR5 protein expression (in a postmortem study) between individuals with major depressive disorder and psychiatrically healthy comparison subjects. METHOD Images of mGluR5 receptor binding were acquired using PET with [(11)C]ABP688, which binds to an allosteric site with high specificity, in 11 unmedicated individuals with major depression and 11 matched healthy comparison subjects. The amount of mGluR5 protein was investigated using Western blot in postmortem brain samples of 15 depressed individuals and 15 matched comparison subjects. RESULTS The PET study revealed lower levels of regional mGluR5 binding in the prefrontal cortex, the cingulate cortex, the insula, the thalamus, and the hippocampus in the depression group relative to the comparison group. Severity of depression was negatively correlated with mGluR5 binding in the hippocampus. The postmortem study showed lower levels of mGluR5 protein expression in the prefrontal cortex (Brodmann's area 10) in the depression group relative to the comparison group, while prefrontal mGluR1 protein expression did not differ between groups. CONCLUSIONS The lower levels of mGluR5 binding observed in the depression group are consonant with the lower levels of protein expression in brain tissue in the postmortem depression group. Thus, both studies suggest that basal or compensatory changes in excitatory neurotransmission play roles in the pathophysiology of major depression.

[1]  G. Nowak,et al.  Effect of MPEP treatment on brain-derived neurotrophic factor gene expression. , 2006, Pharmacological reports : PR.

[2]  A. Young,et al.  Molecular and functional characterization of recombinant human metabotropic glutamate receptor subtype 5 , 1995, Neuropharmacology.

[3]  Brett Connolly,et al.  Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [18F]F-PEB. , 2007, Nuclear medicine and biology.

[4]  Peter Herscovitch,et al.  Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [18F]Cyclofoxy and Positron Emission Tomography , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  Agnieszka Palucha,et al.  Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. , 2007, Pharmacology & therapeutics.

[6]  Olivier Barret,et al.  Quantitation of glutamate mGluR5 receptor with 18F-FPEB PET in humans , 2010, NeuroImage.

[7]  J. Price,et al.  Architectonic subdivision of the human orbital and medial prefrontal cortex , 2003, The Journal of comparative neurology.

[8]  Mark E. Schmidt,et al.  Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  C. Stockmeier,et al.  Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[10]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  Gregor Hasler,et al.  Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. , 2007, Archives of general psychiatry.

[12]  Valerie Treyer,et al.  Evaluation of the Metabotropic Glutamate Receptor Subtype 5 Using PET and 11C-ABP688: Assessment of Methods , 2007, Journal of Nuclear Medicine.

[13]  J. Krystal,et al.  GABA and glutamate systems as therapeutic targets in depression and mood disorders , 2005, Expert opinion on therapeutic targets.

[14]  A. Aliaga,et al.  In vivo and in vitro validation of reference tissue models for the mGluR 5 ligand [ 11 C ] ABP 688 , 2010 .

[15]  W. Drevets,et al.  Discovering Endophenotypes for Major Depression , 2004, Neuropsychopharmacology.

[16]  K. Hashimoto Emerging role of glutamate in the pathophysiology of major depressive disorder , 2009, Brain Research Reviews.

[17]  David F. Meaney,et al.  mGluR5 stimulates gliotransmission in the nucleus accumbens , 2007, Proceedings of the National Academy of Sciences.

[18]  W Zieglgänsberger,et al.  Expression of metabotropic glutamate receptor subtype mRNA (mGluR1-8) in human cerebellum. , 1999, Neuroreport.

[19]  M. Furey,et al.  Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression , 2008, Brain Structure and Function.

[20]  Yves P Auberson,et al.  Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  C. Stockmeier,et al.  Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. , 2009, The international journal of neuropsychopharmacology.

[22]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[23]  K. Saleem,et al.  Complementary circuits connecting the orbital and medial prefrontal networks with the temporal, insular, and opercular cortex in the macaque monkey , 2008, The Journal of comparative neurology.

[24]  Xia Li,et al.  Metabotropic Glutamate 5 Receptor Antagonism Is Associated with Antidepressant-Like Effects in Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.

[25]  J. Endicott,et al.  A diagnostic interview: the schedule for affective disorders and schizophrenia. , 1978, Archives of general psychiatry.

[26]  J. Kemp,et al.  Identification and characterization of a novel splice variant of the metabotropic glutamate receptor 5 gene in human hippocampus and cerebellum. , 2002, Brain research. Molecular brain research.

[27]  A. Aliaga,et al.  In vivo and in vitro Validation of Reference Tissue Models for the mGluR5 Ligand [11C]ABP688 , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  W. Drevets,et al.  Orbitofrontal Cortex Function and Structure in Depression , 2007, Annals of the New York Academy of Sciences.

[29]  M. First,et al.  Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research version (SCID-I RV) , 2002 .

[30]  G. Nowak,et al.  Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats , 2002, Neuropharmacology.

[31]  J. Mann,et al.  The medical management of depression. , 2005, The New England journal of medicine.

[32]  Christine Ryan,et al.  Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers , 2005, Synapse.

[33]  Gregor Hasler,et al.  Evaluation of a bolus/infusion protocol for 11C-ABP688, a PET tracer for mGluR5. , 2010, Nuclear medicine and biology.

[34]  Carlos A. Zarate,et al.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders , 2008, Nature Reviews Drug Discovery.